MEDITOXIN® in Treatment of Crow's Feet Line

Medytox logo

Medytox

Status and phase

Completed
Phase 3

Conditions

Crow's Feet Lines

Treatments

Drug: botulinum toxin type A

Study type

Interventional

Funder types

Industry

Identifiers

NCT03317574
MT01-KR17CFL903

Details and patient eligibility

About

to determine the efficacy and safety of Meditoxin® in treatment of crow's feet line

Enrollment

250 patients

Sex

All

Ages

20 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female of at least 20 to 65 years old
  • Bilaterally symmetrical moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator

Exclusion criteria

  • Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis
  • Patients with allergy or hypersensitivity to the investigational drugs or their components
  • Patients who have bleeding tendency or taking anti-coagulant
  • Female subjects who are pregnant or lactating. Female subjects of childbearing age who have a plan to get pregnant during the study period, or do not use available contraceptive methods (Women of childbearing age should have negative urine pregnancy test results at baseline visit (0 week) prior to the first injection.)
  • Patients who are participating in other clinical trials or have participated in other clinical trials 30 days before screening
  • Patients who are unable to communicate or follow the instructions
  • Patients who are not eligible for this study based on the judgment of an investigator

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

250 participants in 2 patient groups

MEDITOXIN
Experimental group
Treatment:
Drug: botulinum toxin type A
Drug: botulinum toxin type A
BOTOX
Active Comparator group
Treatment:
Drug: botulinum toxin type A
Drug: botulinum toxin type A

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems